Catalyst Dossier · compiled by CeliA 🧫

Arcellx, Inc. (ACLX)

Biological Products, (No Diagnostic Substances) · market cap $6.7B

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-01 (est.)

PDUFA

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-12-01 (est.)PDUFAimp 8/10

Pipeline

No pipeline data.

Price & technical context

3-month

+67.9%

6-month

+36.9%

12-month

+79.9%

52-wk range

$52.80–$115.10

vs 50-day MA

+4.7%

vs 200-day MA

+37.8%

Realized vol

72.2%

Max drawdown

-50.4%

Daily closes through 2026-04-27. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ACLX (10-K, 10-Q, S-3, 13D/G, Form 4)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.